Long-term vision gain after PhotoDynamic Therapy of Choroidal NeoVascularisations in pediatric and young adult patients

Submission date Recruitment status Prospectively registered 11/04/2007 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 22/06/2007 Completed [X] Results [] Individual participant data Last Edited Condition category 25/10/2021 **Eve Diseases**

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Andreas Lipski

Contact details

University Eye Clinic of Essen Hufelandstr. 55 Essen Germany 45138

andreas.lipski@uni-duisburg-essen.de

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers PDT/001

Study information

Scientific Title

Long-term vision gain after PhotoDynamic Therapy of Choroidal NeoVascularisations in pediatric and young adult patients

Acronym

PDT in young CNV

Study objectives

To test efficacy and safety of Photodynamic Therapy (PDT) in young patients with Choroidal Neovascularisations (CNV).

Ethics approval required

Old ethics approval format

Ethics approval(s)

No ethics board approval was sought because this study is a collection of prospective case experiences during the last eight years. By the time the first patients were treated no approval was gained.

Study design

Open-label, uncontrolled, prospective trial.

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Choroidal neovascularization in younger patients

Interventions

Photodynamic therapy with verteporfin (Visudyne). An infusion of verteporfin (for 10 minutes) and laser application to the retina in one study eye (83 seconds) was performed. There was no treatment of the second eye with this method.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

- 1. Visual acuity
- 2. Lesion size

Mean follow-up of 34.4 months.

Secondary outcome measures

Application number (per year).

Mean follow-up of 34.4 months.

Overall study start date

01/08/1999

Completion date

01/07/2006

Eligibility

Key inclusion criteria

- 1. Patients below age 30
- 2. Vision-limiting choroidal neovascularisation

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

15

Key exclusion criteria

Previous (laser) treatment.

Date of first enrolment

01/08/1999

Date of final enrolment

01/07/2006

Locations

Countries of recruitment

Germany

Study participating centre University Eye Clinic of Essen

Essen Germany 45138

Sponsor information

Organisation

University Eye Clinic of Essen (Germany)

Sponsor details

Hufelandstr. 55 Essen Germany D-45138

-

andreas.lipski@uni-duisburg-essen.de

Sponsor type

Hospital/treatment centre

Website

http://www.essen.de/

ROR

https://ror.org/02na8dn90

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University Eye Clinic of Essen (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/03/2008	25/10/2021	Yes	No